Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines

Michael B. Streiff, Bjorn Holmstrom, Aneel Ashrani, Paula L. Bockenstedt, Carolyn Chesney, Charles Eby, John Fanikos, Randolph B. Fenninger, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Paul Hendrie, Nicole Kuderer, Alfred Lee, Jason T. Lee, Mirjana Lovrincevic, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Rita PaschalSanford Shattil, Tanya Siddiqi, Kristi J. Smock, Gerald Soff, Tzu Fei Wang, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, Anita M. Engh

Research output: Contribution to journalArticle

80 Scopus citations

Abstract

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

Original languageEnglish (US)
Pages (from-to)1079-1095
Number of pages17
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines'. Together they form a unique fingerprint.

  • Cite this

    Streiff, M. B., Holmstrom, B., Ashrani, A., Bockenstedt, P. L., Chesney, C., Eby, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., Goldhaber, S. Z., Hendrie, P., Kuderer, N., Lee, A., Lee, J. T., Lovrincevic, M., Millenson, M. M., Neff, A. T., Ortel, T. L., ... Engh, A. M. (2015). Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 13(9), 1079-1095. https://doi.org/10.6004/jnccn.2015.0133